medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2000, Number 6

<< Back Next >>

Alerg Asma Inmunol Pediatr 2000; 9 (6)

Antileukotrienes

Bermúdez UC

Language: Spanish
References: 22
Page: 200-205
PDF size: 269.60 Kb.


ABSTRACT

The asthma is a common illness in the children and its prevalence in this group it has increased. The reasons for this increment are not clear, for what there is not doubt that the asthma is now a problem of health to consider. Fortunately, the knowledge on the physiopathogenic of the asthma is also bigger. It is well known that the asthma is an illness inflammatory chronicle, regulated by a variety of mediators, where the leukotrienes are some of the most important. For that the inhibition or these mediators’ blockade is of supreme importance in the therapeutic of the asthmatic illness. Presently article the characteristic pharmacological and their applications of the diverse existent antileukotrienes are described at the present time.


REFERENCES

  1. Valacer DJ. Childhood asthma: Causes, epidemiological factors and complications. Drugs 2000; 59(Suppl. 1): 1-8: discussion 43 -45.

  2. Herderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121: 684 - 97.

  3. García ML, Schuster A. New perspectives for asthma treatment: Antileukotriene drugs. Pediatr Allergy Immunol 1999; 10: 77- 88.

  4. Middleton E Jr, Ellis EF, Yunginger JW, Reed CE, Adkinson NF, Busse WW. Antileukotriene drugs in the treatment of asthma. Allergy, Principles and Practice, volume 1, 5a ed. 1998.

  5. Jefrey MD, Elliot I, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. The New England Journal of Medicine 1999; 340: 197 - 206.

  6. Loe DW, Almquist KC, Deeley RG, Cole SPC. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996; 271: 9675 - 82.

  7. Wetterholm A, Haeggstrom JZ. Leukotriene A4 hydrolase: An anion activated peptidase. Biochem Biophys Acta 1992; 1123: 275 - 81.

  8. Kawashima H, Kusunose E, Thompson CM, Strobel HW. Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Arch Biochem Biophys 1997; 347: 148 - 54.

  9. Yokomizo T, Ogawa Y, Uozumi N, Kume K, Izumi T, Shimuzu T. cDNA cloning, expression, and mutagenesis stay of leukotriene B4 12-hydroxydehydrogenase. J Biol Chem 1996; 271: 2844 - 50.

  10. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. AG-protein coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387: 620 - 4.

  11. Lammers JWJ, Minette P, McCusker M et al. The role of pirenzepine sensitive muscarinic receptors in vagally mediated bronchoconstriction in humans. Am Rev Respir Dis 1989; 139: 446 - 449.

  12. Gawchik SM, Saccar CL. Role of antileukotriene agents in asthma therapy. J Am Osteopath Assoc 2000; 100: (32) 37 - 43.

  13. Smith l, Shelhamer J, Kaliner J. Cholinergic nervous system and immediate hypersensitivity II. An analysis of papillary responses. J Allergy Clin Immunol 1980; 66: 374 - 378.

  14. McFadden E, Luparello T, Lyons H et al. The mechanism of action of suggestion in the inaction of acute asthmatic attacks. Psychosom Med 1969; 31: 134 – 143.

  15. Neild JE, Cameron IR. Bronchoconstriction in response to suggestion: Its prevention by an inhaled anticholinergic agent. Br Med J 1985; 290: 674.

  16. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma: Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992; 145: 746 - 9.

  17. Sanak M, Simon HU, Szczeklil A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induce asthma. Lancet 1997; 350: 1599 - 600.

  18. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859 - 71.

  19. Spector SL, Smith LJ, Glass M. Accolate Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204, 219 a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618 -23.

  20. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in-patients with asthma: A randomized controlled trial. JAMA 1996; 275: 931 - 6.

  21. Tamaoki J, Kondo M, Sakai N et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155: 1235 - 40.

  22. Awni WM, Braeckman RA, Granneman GR, With Dube LM. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimes of zileuton 600 mg in healthy volunteers. Clin Pharmacokinet 1995; 29(suppl.2): 9 - 21.




2020     |     www.medigraphic.com